J 2022

Small non-coding RNA profiling in breast cancer: plasma U6 snRNA, miR-451a and miR-548b-5p as novel diagnostic and prognostic biomarkers

ZAVESKY, Ludek, Eva JANDÁKOVÁ, Vít WEINBERGER, Luboš MINÁŘ, Veronika HANZIKOVA et. al.

Basic information

Original name

Small non-coding RNA profiling in breast cancer: plasma U6 snRNA, miR-451a and miR-548b-5p as novel diagnostic and prognostic biomarkers

Authors

ZAVESKY, Ludek (203 Czech Republic, guarantor), Eva JANDÁKOVÁ (203 Czech Republic, belonging to the institution), Vít WEINBERGER (203 Czech Republic, belonging to the institution), Luboš MINÁŘ (203 Czech Republic, belonging to the institution), Veronika HANZIKOVA (203 Czech Republic), Daniela DUSKOVA (203 Czech Republic), Adela FARIDOVA (203 Czech Republic), Radovan TURYNA (203 Czech Republic), Ondrej SLANAR (203 Czech Republic), Ales HORINEK (203 Czech Republic) and Milada KOHOUTOVA (203 Czech Republic)

Edition

MOLECULAR BIOLOGY REPORTS, DORDRECHT, Springer, 2022, 0301-4851

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10608 Biochemistry and molecular biology

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.800

RIV identification code

RIV/00216224:14110/22:00125182

Organization unit

Faculty of Medicine

UT WoS

000739770300002

Keywords in English

Biomarker; Breast cancer; microRNA; miR-451a; miR-548b-5p; U6 snRNA

Tags

International impact, Reviewed
Změněno: 20/7/2022 09:28, Mgr. Tereza Miškechová

Abstract

V originále

Background Breast cancer is a leading cause of cancer-related death in women. Most cases are invasive ductal carcinomas of no special type (NST breast carcinomas). Methods and Results In this prospective, multicentric biomarker discovery study, we analyzed the expression of small non-coding RNAs (mainly microRNAs) in plasma by qPCR and evaluated their association with NST breast cancer. Large-scale expression profiling and subsequent validations have been performed in patient and control groups and compared with clinicopathological data. Small nuclear U6 snRNA, miR-548b-5p and miR-451a have been identified as candidate biomarkers. U6 snRNA was remarkably overexpressed in all the validations, miR-548b-5p levels were generally elevated and miR-451a expression was mostly downregulated in breast cancer groups. Combined U6 snRNA/miR-548b-5p signature demonstrated the best diagnostic performance based on the ROC curve analysis with AUC of 0.813, sensitivity 73.1% and specificity 82.6%. There was a trend towards increased expression of both miR-548b-5p and U6 snRNA in more advanced stages. Further, increased miR-548b-5p levels have been partially associated with higher grades, multifocality, Ki-67 positivity, and luminal B rather than luminal A samples. On the other hand, an association has been observed between high miR-451a expression and progesterone receptor positivity, lower grade, unifocal samples, Ki-67-negativity, luminal A rather than luminal B samples as well as improved progression-free survival and overall survival. Conclusions Our results indicated that U6 snRNA and miR-548b-5p may have pro-oncogenic functions, while miR-451a may act as tumor suppressor in breast cancer.